AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Lineage Cell Therapeutics Bolstered by Strategic Partnerships and Promising Trial Results, Analyst Reiterates Buy Rating with $9.00 Price Target.
ByAinvest
Wednesday, Aug 27, 2025 2:32 pm ET1min read
Lineage Cell Therapeutics has a Buy rating from Joseph Pantginis at H.C. Wainwright, with a price target of $9.00. Pantginis cites strategic partnerships, including a $12 million deal with William Demant Invest A/S for its hearing loss program, and promising trial results for its OpRegen program in dry-AMD patients. The analyst expects potential funding from a CIRM grant and development milestones from Roche to strengthen Lineage's financial and strategic position. Pantginis has an average return of -7.9% and a 39.80% success rate.
Lineage Cell Therapeutics Inc. (LCTX) has received a Buy rating from Joseph Pantginis at H.C. Wainwright, with a price target of $9.00. Pantginis highlights strategic partnerships and promising trial results as key drivers for the company's potential growth.The analyst cites a $12 million research collaboration with William Demant Invest A/S (WDI) for Lineage's auditory neuronal cell transplant, ReSonance (ANP1), for the treatment of hearing loss. This partnership, announced in late 2024, involves preclinical development activities and joint funding by WDI [2]. Additionally, Pantginis points to promising trial results for Lineage's OpRegen program in dry age-related macular degeneration (AMD) patients.
Pantginis expects potential funding from the California Institute for Regenerative Medicine (CIRM) and development milestones from Roche to further strengthen Lineage's financial and strategic position. The analyst's average return is -7.9%, with a 39.80% success rate [1].
In the last quarter, analysts' ratings for Lineage Cell Therapeutics varied from bullish to bearish, with one analyst maintaining a Buy rating and another maintaining a $9.00 price target [1]. This suggests a mix of optimism and caution among financial experts regarding the company's future prospects.
References:
[1] https://www.benzinga.com/insights/analyst-ratings/25/08/47366715/5-analysts-assess-lineage-cell-therapeutics-what-you-need-to-know
[2] https://www.marketscreener.com/news/lineage-cell-therapeutics-inc-announces-research-collaboration-with-william-demant-invest-to-devel-ce7c50ded98bf621
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet